Orforglipron: What to Know About This Next Generation Weight-Loss Pill

There’s always a media buzz when a new weight-loss drug hits the market. Or when new data shows that a medication can effectively lower body weight. If weight loss is something that you’re interested in, medication might present a way forward.

If you've been exploring medication options to help you manage your weight, you may have stumbled across injections, such as Wegovy (semaglutide) and Zepbound (tirzepatide). For some, the thought of regularly giving yourself injections may seem overwhelming or uncomfortable.

Fortunately, new weight-loss pills are emerging as alternative options to injectable glucagon-like peptide-1 (GLP-1) receptor agonists. Oral Wegovy (semaglutide) tablets started the trend in December 2025, and orforglipron may be next in line.

6 Ways to Advocate for Yourself at the Doctor’s Office If You Have a Larger Body

Written by Christina Palmer, MD

What are ‘glipron’ medications?

A new group of medications, known as “gliprons,” are showing promise in clinical trials for weight loss and Type 2 diabetes. Their nickname comes from their suffixes, or the ending of their generic names. They work by mimicking the effects of natural GLP-1 in the body.

Orforglipron is currently the main example. It’s an oral capsule taken once daily. It’s a GLP-1 receptor agonist that has similar effects as other medications of its type. Orforglipron is made by Eli Lilly, the same company that makes Mounjaro (tirzepatide), Trulicity (dulaglutide), and many other diabetes medications.

Danuglipron was a similar oral tablet meant to work like orforglipron, but its manufacturer has stopped developing it.

Good to know: Try not to confuse gliprons with gliptins. Gliptins are a different group of Type 2 diabetes medications. Januvia (sitagliptin) and Tradjenta (linagliptin) are two common gliptins.

What happened to danuglipron?

Danuglipron was a once-daily, oral GLP-1 receptor agonist being developed by Pfizer. It initially showed promising results in clinical trials. But, during a dose study, one participant experienced a possible drug-related liver injury. The injury went away after they stopped the medication. 

Although overall liver enzyme levels were similar to those seen with other approved GLP-1 medications, Pfizer decided that danuglipron’s potential liver risks outweighed its benefits. 

After reviewing all clinical data and regulatory input, Pfizer officially discontinued danuglipron in 2025. The company had already stopped work on a twice-daily version due to high rates of stomach-related side effects.

How is orforglipron different from other weight-loss medications?

Orforglipron is similar to other GLP-1 receptor agonists. But it's made using different materials and processes.

EXPERT PICKS: WHAT TO READ NEXT

• Upcoming options: GoodRx pharmacists review other weight-loss medications that are being studied in clinical trials.

• Convenience and impact: Discover what to know about weight-loss pills that are already FDA approved for use.

• GLP-1 pills: Orforglipron isn’t the only GLP-1 pill in development for weight loss. Read on for an overview of what to know about similar products in the works.

• A holistic approach: Combining weight-loss medication with lifestyle changes can improve your chances of success. Here, one person shares how a new diet and mindset helped keep him at his ideal body weight.

Traditional GLP-1 receptor agonists, such as Wegovy, are peptides (chains of amino acids) that resemble a gut hormone called GLP-1. This hormone plays a role in digestion and blood glucose (sugar) regulation. These medications mimic GLP-1’s natural effects, helping you feel fuller for longer and lessening your appetite. This often leads to weight loss.

But these peptides can’t travel through your stomach very well due to their size. Plus, enzymes (proteins) and acids in your gut can break peptides apart, rendering them ineffective. This is why they’re typically made as injections, not pills. Oral options, such as Rybelsus (semaglutide) and Wegovy tablets, are made with absorption-enhancing ingredients and have specific instructions for use.

Gliprons address this issue. Like many other medications, they’re small-molecule drugs made using chemical synthesis rather than peptides or proteins. They’re able to start working after you swallow a dose and don’t generally need to be timed around meals. Dubbed “nonpeptide” GLP-1 receptor agonists, they activate GLP-1 in their own way.

As an added bonus, experts predict that orforglipron will be easier and cheaper to produce in bulk. This may translate to additional savings at the pharmacy.

Keep in mind: There are still ways to save on traditional GLP-1 medications for weight loss. For example, if you're new to using GoodRx for Wegovy savings, pay an introductory price for the first two fills of $199 per month for the injection and $149 per month for the pill (only available for certain doses). For future fills and for other Wegovy doses, pay $349 per month for the injection and $299 per month for the pill.

Non-GLP-1 weight-loss medications

Other FDA-approved weight-loss medications are available. They work in a different way than GLP-1 receptor agonists.

• Contrave: This oral tablet contains naltrexone, an opioid blocker, and bupropion, an antidepressant. It reduces cravings and hunger.

• Qsymia: This oral capsule also contains two active ingredients. Phentermine is a stimulant and topiramate ER is an anti-seizure medication. Together, they can lessen cravings and hunger.

• Orlistat: This oral capsule helps your body absorb less dietary fat. It’s available with a prescription as name-brand Xenical and over the counter as name-brand Alli.

• Phentermine: A short-term weight loss treatment, this oral tablet is a stimulant that reduces appetite. Benzphetamine, diethylpropion, and phendimetrazine are alternative options that work in a similar way.

• Imcivree: Unlike the other medications, Imcivree isn’t a pill. It’s an under the skin injection that promotes weight loss for those with certain genetic conditions. Its active ingredient is setmelanotide.

Many more medications are taken off-label for weight loss. Metformin, topiramate (Topamax), and bupropion are three options out of many. They tend to cause weight loss as a side effect.

Are there clinical trial results for orforglipron?

Yes, some recent clinical trial results are available for orforglipron. Here’s some of what the studies say so far:

• Weight loss: In phase 2 study, orforglipron helped adults lose an average of up to 15% of their initial body weight. These results were seen after about 36 weeks (8 months) of daily use. Everyone in the study was considered overweight or obese. More recent results from orforglipron's phase 3 ATTAIN-1 trial showed that people taking the highest dose (36 mg) for 72 weeks (about 17 months) lost an average of about 12% of their initial body weight.

• Type 2 diabetes: Orforglipron has also been tested by adults with Type 2 diabetes in a phase 3 trial. After 40 weeks (9 months), orforglipron reduced A1C levels by about 1.3% to 1.6% from a baseline of 8%. People taking the highest dose also lost an average 8% of their starting body weight — that’s around 16 lbs.

What are the side effects of orforglipron?

All medications can cause side effects, including orforglipron. So far, clinical studies suggest that orforglipron has similar side effects to injectable GLP-1 receptor agonists. Nausea, diarrhea, and stomach pain are all possible complaints.

We’ll learn more about risks and side effects as clinical trials go on.

When will orforglipron be available?

The FDA placed orforglipron in the second wave of medications selected for its new Commissioner’s National Priority Voucher (CNPV) program. Being part of this program can help fast-track FDA review for treatments that show strong potential to address important health needs.

Eli Lilly, orforglipron’s manufacturer, says it expects U.S. regulatory approval as early as March 2026.

In the meantime, consumers and healthcare professionals should stay updated as new data and announcements are released. Be sure to check back with GoodRx for the latest information.

What other new weight-loss drugs are being developed?

Weight-loss medications are a hot topic of research. Many pharmaceutical companies are working on developing weight-loss medications in clinical trials.

Gliprons aside, two examples of many include:

• Retatrutide: An under-the-skin injection, retatrutide targets three hormones in the body — GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. A phase 2 study found it can help people lose up to 24% of their starting body weight.

• APH-012: This once-daily pill mimics the effects of “weight-loss surgery,” better known as gastric bypass surgery.

Why trust our experts?

Written by:

Joshua Murdock, PharmD, BCBBS

Joshua Murdock, PharmD, BCBBS, is a licensed pharmacist in Arizona, Colorado, and Rhode Island. He has worked in the pharmacy industry for more than 10 years and currently serves as a pharmacy editor for GoodRx.

Reviewed by:

Alyssa Billingsley, PharmD

Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.

Our editorial standards

Meet our experts